MEDIPHARM LABS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.075 CAD | 0.00% |
|
-6.25% | +15.38% |
| Jun. 26 | Transcript : MediPharm Labs Corp. - Shareholder/Analyst Call | |
| Jun. 20 | MediPharm Labs Acquires Rights for Advanced Medical Cannabis Products From Remidose Aerosols | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +15.38% | 22.09M | D | ||
| +27.29% | 5.63B | B- | ||
| -33.07% | 3.57B | C+ | ||
| -3.24% | 3.08B | C | ||
| -24.56% | 2.65B | B- | ||
| -10.17% | 2.29B | - | D+ | |
| +46.81% | 1.99B | - | ||
| +48.03% | 1.54B | - | ||
| -11.69% | 1.45B | - | - | |
| +43.81% | 1.39B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LABS Stock
- Ratings MediPharm Labs Corp.
